KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Charles River Laboratories International (CRL) EBIT (2016 - 2025)

Charles River Laboratories International has reported EBIT over the past 17 years, most recently at -$283.4 million for Q4 2025.

  • For Q4 2025, EBIT fell 69.03% year-over-year to -$283.4 million; the TTM value through Dec 2025 reached $25.2 million, down 88.93%, while the annual FY2025 figure was $25.2 million, 88.93% down from the prior year.
  • EBIT for Q4 2025 was -$283.4 million at Charles River Laboratories International, down from $133.8 million in the prior quarter.
  • Over five years, EBIT peaked at $187.4 million in Q2 2022 and troughed at -$283.4 million in Q4 2025.
  • A 5-year average of $105.5 million and a median of $143.2 million in 2021 define the central range for EBIT.
  • Biggest five-year swings in EBIT: soared 79.18% in 2021 and later tumbled 226.15% in 2024.
  • Year by year, EBIT stood at $172.8 million in 2021, then decreased by 5.21% to $163.8 million in 2022, then fell by 18.86% to $132.9 million in 2023, then tumbled by 226.15% to -$167.7 million in 2024, then plummeted by 69.03% to -$283.4 million in 2025.
  • Business Quant data shows EBIT for CRL at -$283.4 million in Q4 2025, $133.8 million in Q3 2025, and $100.1 million in Q2 2025.